Moderna – one of the companies who have become much better-known thanks to COVID vaccines – are proposing to start trials of a vaccine for HIV.

They are working on two possible projects, based on the mRNA technology that has come ahead in leaps and bounds thanks to the massive investment of time, money and focus that the fight against COVID has seen.

They note: “mRNA-1644 is a novel approach to HIV vaccine strategy in humans designed to elicit broadly neutralizing HIV-1 antibodies (bNAbs) and is being developed in collaboration with the International AIDS Vaccine Initiative (IAVI) and the Bill and Melinda Gates Foundation (BMGF). A Phase 1 study for mRNA-1644 will use iterative human testing to validate the approach and antigens and multiple novel antigens will be used for germline-targeting and immuno-focusing.

“A second approach, mRNA-1574, is being evaluated in collaboration with the National Institutes of Health (NIH) and includes multiple native-like trimer antigens. The Company expects to begin phase 1 clinical trials for both mRNA-1644 and mRNA-1574 in 2021.”

Recent estimates suggest there were around 105,200 people living with HIV in the UK in 2019. Of these, around 6,600 are undiagnosed.